APP and Alzheimer disease: Although future studies should confirm that no other substrates of BACE1 are affected by TAT-APPsweBBP, our current findings provide evidence for a novel strategy for alternative design of BACE1 inhibitors and suggest that TAT-APPsweBBP may be a novel, safe and effective APP substrate-based BACE1 inhibitor for the treatment of AD.